This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What Makes Krystal Biotech, Inc. (KRYS) a New Buy Stock
by Zacks Equity Research
Krystal Biotech, Inc. (KRYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Krystal Biotech, Inc. (KRYS) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Krystal Biotech, Inc. (KRYS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here's Why Momentum in Krystal Biotech, Inc. (KRYS) Should Keep going
by Zacks Equity Research
Krystal Biotech, Inc. (KRYS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Krystal Biotech, Inc. (KRYS) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Krystal Biotech, Inc. (KRYS) delivered earnings and revenue surprises of 157.69% and 119.92%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Krystal Biotech, Inc. (KRYS) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Krystal Biotech, Inc. (KRYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts See a 42.55% Upside in Krystal Biotech, Inc. (KRYS): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Krystal Biotech, Inc. (KRYS) points to a 42.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Krystal (KRYS) Up 5% on Sale of FDA's Priority Review Voucher
by Zacks Equity Research
Krystal (KRYS) announces the sale of its priority review voucher for a consideration of $100 million. The stock of the company rises 5.2% on the news.
Krystal Biotech, Inc. (KRYS) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Krystal Biotech, Inc. (KRYS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Krystal's (KRYS) Dermatology Drug Gets FDA Nod, Stock Up 10%
by Zacks Equity Research
Krystal's (KRYS) stock soars 10% on Friday after the company announces the FDA approval of Vyjuvek for the treatment of patients six months of age or older with dystrophic epidermolysis bullosa.
Krystal Biotech, Inc. (KRYS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Krystal Biotech, Inc. (KRYS) delivered earnings and revenue surprises of -3.13% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Company News for Nov 30, 2021
by Zacks Equity Research
Companies in the news are: KRYS, ADGI, NRXP, HTZ
New Strong Sell Stocks for June 8th
by Zacks Equity Research
ASLN, CANG, ESLT, GCI, and KRYS have been added to the Zacks Rank #5 (Strong Sell) List on June 8, 2021.
New Strong Sell Stocks for May 28th
by Zacks Equity Research
ACET, FURY, KRYS, MRSN, and NBEV have been added to the Zacks Rank #5 (Strong Sell) List on May 28, 2021
New Strong Sell Stocks for May 21st
by Zacks Equity Research
ATHM, INVO, FOUR, KRYS, and RMAX have been added to the Zacks Rank #5 (Strong Sell) List on May 21, 2021
Krystal Biotech, Inc. (KRYS) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Krystal Biotech, Inc. (KRYS) have what it takes to be a top stock pick for momentum investors? Let's find out.
The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech
5 Biotech Stocks Up More Than 100% This Year So Far
by Indrajit Bandyopadhyay
The biotech sector recovers on the back of rising M&A activities and pipeline successes in 2019 after a dismal 2018. Here we discuss five biotech companies recording impressive growth.
Krystal Biotech, Inc. (KRYS) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Krystal Biotech, Inc. (KRYS).
Here's Why Krystal Biotech, Inc. (KRYS) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Krystal Biotech, Inc. (KRYS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Krystal (KRYS) in Focus: Stock Moves 5.1% Higher
by Zacks Equity Research
Krystal (KRYS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Vertex (VRTX) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Krystal Biotech Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Krystal Biotech has been struggling lately, but the selling pressure may be coming to an end soon.
Krystal Biotech (KRYS) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Krystal Biotech, Inc. (KRYS).
Can the Rally in Krystal Biotech (KRYS) Shares Continue?
by Zacks Equity Research
Krystal Biotech, Inc. (KRYS) has been on the move lately as the stock has risen by 24.5% in the past four weeks, and it is currently trading well above its 20-Day SMA
Top Ranked Momentum Stocks to Buy for May 31st
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, May 31st: